TNFR2 - target for therapeutics against neurodegenerative diseases?

Adv Exp Med Biol. 2011:691:567-73. doi: 10.1007/978-1-4419-6612-4_59.

Authors

Ingrid M Nijholt¹, Ivica Granic, Paul G M Luiten, Ulrich L M Eisel

Affiliation

¹ Department of Molecular Neurobiology, University of Groningen, Groningen, The Netherlands. [email protected]

PMID: 21153362
DOI: 10.1007/978-1-4419-6612-4_59

No abstract available

MeSH terms

Animals
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Mice
Models, Biological
Neurodegenerative Diseases / drug therapy*
Neuroprotective Agents / pharmacology
Neuroprotective Agents / therapeutic use
Receptors, Tumor Necrosis Factor, Type II / antagonists & inhibitors*
Receptors, Tumor Necrosis Factor, Type II / metabolism
Signal Transduction / drug effects
Small-Conductance Calcium-Activated Potassium Channels / metabolism
Tumor Necrosis Factor-alpha / metabolism

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Neuroprotective Agents
Receptors, Tumor Necrosis Factor, Type II
Small-Conductance Calcium-Activated Potassium Channels
Tumor Necrosis Factor-alpha